Clinical trials: Shy-Drager Syndrome
Symptomatic Neurogenic Orthostatic Hypotension
Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension
To evaluate the time to treatment intervention in patients with Parkinson's Disease (PD), Multiple System Atrophy (MSA), Pure Autonomic Failure (PAF), Non-Diabetic Autonomic Neuropathy (NDAN) or Dopamine Beta Hydroxylase (DBH)…
- Trial name
- RESTORE (NCT02586623)
- Testing
- Droxidopa capsules
- Where
- 168 sites in United States
- Volunteers
- 453 people
- Sponsor
- H. Lundbeck A/S
Parkinson Disease, Multisystem Atrophy
Proof of Mechanism Study to Evaluate Binding of Alfa-synuclein
The overall goal of this protocol is to: Evaluate [18F]UCB-2897 as an α-synuclein targeted radiopharmaceutical. The primary objective is: Confirm a specific α -synuclein signal with [18F]UCB-2897 in participants with PD and/or…
- Conditions
- Parkinson Disease, Multisystem Atrophy, Healthy Volunteer
- Trial name
- NCT05274568
- Testing
- [18F]UCB-2897
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Invicro
Hypertension, Pure Autonomic Failure
Local Heat Stress in Autonomic Failure Patients With Supine Hypertension
Patients with autonomic failure are characterized by disabling orthostatic hypotension (low blood pressure on standing), and at least half of them also have high blood pressure while lying down (supine hypertension).
- Conditions
- Hypertension, Pure Autonomic Failure, Multiple System Atrophy, Autonomic Failure
- Trial name
- NCT02417415
- Testing
- Passive heat stress, Control (non-heating)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Vanderbilt University
Neurodegenerative Diseases, Parkinson Disease
Neurodegenerative Diseases Progression Markers (MARKERS-NDD)
MARKERS-NDD is a prospective, observational, longitudinal study, which aims to collect data from patients affected by neurodegenerative diseases (NDD) followed longitudinally for routine examinations performed as part of normal…
- Conditions
- Neurodegenerative Diseases, Parkinson Disease, Synucleinopathies, Lewy Body Disease
- Trial name
- MARKERS-NDD (NCT06596746)
- Testing
- Observation
- Where
- Italy
- Volunteers
- 600 people
- Sponsor
- Casa di Cura San Raffaele Cassino
Late Onset Sporadic Cerebellar Ataxia
Sporadic Degenerative Ataxia With Adult Onset: Natural History Study
The key goals of SPORTAX-NHS is to compare the phenotype of multiple system atrophy of cerebellar type (MSA-C) and sporadic adult onset ataxia of unknown aetiology (SAOA) and to determine the rate of disease progression in both…
- Trial name
- SPORTAX-NHS (NCT02701036)
- Where
- 14 sites in Austria, Germany and 3 more
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Ataxia Study Group
Sleep Apnea Syndromes, Multiple System Atrophy
Assessment of Ambulatory Polygraphy in the Detection of Sleep Apnea in Multiple System Atrophy (SAMSA)
The purpose of this study is to determine whether ambulatory polygraphy during a short hospitalization in a neurology unit has the same performance than inpatient polysomnography, the actual gold standard, in the diagnosis of…
- Trial name
- NCT00743561
- Testing
- Polysomnography, ambulatory polygraphy
- Where
- 2 sites in France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Bordeaux
Parkinson Disease, Progressive Supranuclear Palsy
Biomarkers in Parkinsonian Syndromes
This is a prospective observational study to identify biomarkers in parkinson syndromes. Patients with parkinsonian syndromes at the early stages of disease will be recruited and will be followed up until their established…
- Conditions
- Parkinson Disease, Progressive Supranuclear Palsy, Multiple System Atrophy, Atypical Parkinsonism
- Trial name
- PROATYP (NCT06501469)
- Where
- Greece
- Volunteers
- 200 people
- Sponsor
- Non-profit organization for scientific research in Parkinson's disease and related disorders
Multiple System Atrophy
A Futility Trial of Sirolimus in Multiple System Atrophy
Single-center, randomized, placebo-controlled, phase-II, futility clinical trial to determine if oral sirolimus is of sufficient promise to slow disease progression in MSA, prior to embarking on a large-scale and costly phase III…
- Trial name
- NCT03589976
- Testing
- Sirolimus 2 MG
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- NYU Langone Health
Multiple System Atrophy, Parkinson Variant (Disorder), Parkinson Disease
Mobility in Atypical Parkinsonism: a Trial of Physiotherapy
Patients with atypical parkinsonism often show gait and mobility impairment manifesting in early disease stages. In order to maintain mobility and physical autonomy as long as possible for these patients, we will examine the…
- Conditions
- Multiple System Atrophy, Parkinson Variant (Disorder), Parkinson Disease, Progressive Supranuclear Palsy
- Trial name
- Mobility_APP (NCT04608604)
- Testing
- Physiotherapy
- Where
- Austria
- Volunteers
- 180 people
- Sponsor
- Victoria Sidoroff
Parkinson Disease, Multiple System Atrophy
Evaluation of the Efficacy of a Two-week EMST on Dysphagia in Parkinsonian Patients
This is an interventional therapy study designed to evaluate the efficacy of a two-week intervention, i.e. training with a specialized exhalation training device (called expiratory muscle strength training; EMST150 or EMST75…
- Conditions
- Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
- Trial name
- EMST-PS (NCT05139342)
- Testing
- expiratory muscle strentgh training (EMST)
- Where
- 3 sites in Germany
- Volunteers
- 75 people
- Sponsor
- Kliniken Beelitz GmbH
Hypertension, Pure Autonomic Failure
Overnight Trials With Heat Stress in Autonomic Failure Patients With Supine Hypertension
Patients with autonomic failure are characterized by disabling orthostatic hypotension (low blood pressure on standing), and at least half of them also have high blood pressure while lying down (supine hypertension).
- Conditions
- Hypertension, Pure Autonomic Failure, Multiple System Atrophy, Autonomic Failure
- Trial name
- NCT03042988
- Testing
- Heating pad
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Vanderbilt University Medical Center
Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy
A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa
The purpose of this study is to see whether droxidopa is effective in treating symptoms of neurogenic orthostatic hypotension in patients with Primary Autonomic Failure (Pure Autonomic Failure, Multiple System Atrophy…
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy, Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency
- Trial name
- NOH301 (NCT00782340)
- Testing
- Droxidopa
- Where
- 21 sites in United States, Canada
- Volunteers
- 263 people
- Sponsor
- Chelsea Therapeutics
Multiple System Atrophy - Parkinsonian Subtype (MSA-P), Multiple System Atrophy, MSA
The Study of Safety and Preliminary Efficacy of Aleeto in Patients With MultIple System Atrophy
This is a single-center, prospective, randomized, open-label, blinded outcome assessment (PROBE) study. At the end of the PROBE study, patients who have completed the study may opt to enter the open-label extension (OLE) study.
- Trial name
- SPRITE (NCT06765733)
- Testing
- Aleeto
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Tiantan Hospital
Multiple System Atrophy
"An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs (Hope Biosciences - Adipose Derived Mesenchymal Stem Cells) for the Treatment of Multiple System Atrophy."
This expanded access protocol is part of IND 32226 to evaluate efficacy and safety of multiple intravenous administrations of allogeneic HB-adMSCs for the treatment of Multiple System Atrophy for up to 7 adult patients who pass…
- Trial name
- NCT07238062
- Testing
- HB-adMSCs - Hope Biosciences Adipose Derived Mesenchymal Stem Cells
- Where
- United States
- Sponsor
- Hope Biosciences Research Foundation
Parkinson Disease, MSA - Multiple System Atrophy
Differential Diagnosis Between Parkinson's Disease and Multiple System Atrophy Using Digital Speech Analysis
Parkinson's disease (PD) is the second most common neurodegenerative disease. Multiple system atrophy (MSA) is a relentlessly progressing rare neurodegenerative disease of unknown etiology.
- Trial name
- Voice4PD-MSA (NCT03577483)
- Testing
- voice recordings
- Where
- 2 sites in France
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Parkinsonian Syndromes, Parkinson's Disease
Biomarkers in Parkinsonian Syndromes
Parkinson disease (PD), multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) are neurodegenerative disorders. PD and MSA are alpha-synucleinopathies, which are characterized by the abnormal accumulation of…
- Conditions
- Parkinsonian Syndromes, Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
- Trial name
- BIOPARK (NCT02114242)
- Testing
- CSF, blood and urine sampling, clinical measures of disease severity and progression
- Where
- 3 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Bordeaux
Parkinson's Disease, Multiple System Atrophy, Parkinson Variant
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
The objective of this study is to describe disease progression in study participants diagnosed with early Parkinson's Disease or Multiple System Atrophy - Parkinsonian Type up to 18 months as delineated by clinical and…
- Conditions
- Parkinson's Disease, Multiple System Atrophy, Parkinson Variant, Multiple System Atrophy
- Trial name
- NCT05699460
- Testing
- This is an observational study.
- Where
- 11 sites in United States, Poland
- Volunteers
- 73 people
- Sponsor
- AskBio Inc
Parkinson's Disease (PD), Parkinsonism
Identifying Biomarkers of Parkinson's Disease Using Magnetic Resonance Imaging (MRI)
This study is designed to determine if magnetic resonance imaging (MRI) measures can be used to diagnose and monitor the progression of Parkinson's disease (PD) while distinguishing between PD and parkinsonisms [conditions that…
- Conditions
- Parkinson's Disease (PD), Parkinsonism, Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA)
- Trial name
- NCT01888185
- Where
- United States
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Multiple System Atrophy, Parkinsons Disease
Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies
This phase I double-blind study focuses on the safety and feasibility of implanting autologous peripheral nerve tissue (PNT) into the substantia nigra area of the brain in persons who have been diagnosed with either Parkinson's…
- Trial name
- LEAP (NCT06683365)
- Testing
- Sural Nerve Graft to the Substantia Nigra
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Craig van Horne, MD, PhD
Primary Parkinsonism, Secondary Vascular Parkinson Disease
Application of Machine Learning Method in Validation of Screening Cognitive Test for Parkinsonisms
Based on a prospectively collected data analysis, a new tool, namely CoMDA (Cognition in Movement Disorders Assessment) is developed by merging each item of Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment…
- Conditions
- Primary Parkinsonism, Secondary Vascular Parkinson Disease, Multiple System Atrophy, Supranuclear Palsy, Progressive
- Trial name
- CoMDA-ML-P (NCT04858893)
- Testing
- CoMDA associated with Neural Net 91 classificator
- Where
- Italy
- Volunteers
- 562 people, healthy volunteers welcome
- Sponsor
- Ospedale Generale Di Zona Moriggia-Pelascini